The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved to ...

The Food and Drug Administration has approved Zepbound, a GLP-1 weight-loss drug from Eli Lilly & Co., for the treatment of moderate to severe sleep apnea certain patients with obesity. Photo courtesy ...

SleepScriptMD offers board-certified physician-reviewed, non-addictive sleep prescriptions online — no office visits ...

The Food and Drug Administration approved Zepbound as the first prescription medicine to treat sleep apnea on Friday—marking a significant win for the drug company Eli Lilly, which had Zepbound ...

Millions of older Americans suffering from insomnia regularly use prescription sleep medications, despite the risk of serious side effects-such as falls, broken bones, cognitive impairment and ...

The US Food and Drug Administration (FDA) has approved the obesity treatment tirzepatide (Zepbound, Eli Lilly) for treating moderate to severe obstructive sleep apnea (OSA) in adults with obesity. The ...

Obstructive sleep apnea or OSA affects nearly a billion people across the globe. It robs people of their sleep — they stop breathing sometimes 20 to 50 to 100 times a night and are abruptly awakened.

According to the National Sleep Foundation’s 2025 “Sleep in America” poll results, four out of every 10 American adults say they have trouble falling asleep at least three nights a week. When sleep is ...

Centessa Pharmaceuticals executives will be breathing a sigh of relief as its stock price recovered after a drop caused by the release of Phase IIa data on its experimental sleep disorder therapy.

Tens of millions of Americans struggle to sleep at night, and many of them turn to sleeping pills for relief. Prescription and over-the-counter sleep aids are especially popular among older adults. A ...

WASHINGTON — Jazz Pharmaceuticals lost its bid to overturn the approval of another company’s rival sleep drug when a D.C. federal judge ruled that the FDA did not violate the Orphan Drug Act when ...